-
A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012;32:171-8. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012;31:42-8. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks.
Lefebvre J, Demers S, Bujold E, Nicolaides KH, Girard M, Brassard N, Audibert F.
Ultrasound Obstet Gynecol 2012;40:288-92. -
Maternal hemodynamics at 11-13 weeks' gestation and the risk of preeclampsia.
Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2012;40:28-34. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2011;31:196-201. -
Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia.
Sifakis S, Akolekar R, Mantas N, Kappou D, Nicolaides KH.
Hypertens Pregnancy 2011;30:74-82. -
Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks.
Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH.
Hypertens Pregnancy 2011;30:93-107. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Maternal serum adiponectin at 11-13 weeks of gestation in preeclampsia.
Nanda S, Yu CK, Giurcaneanu L, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;29:208-15. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2010;30:1026-31. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010;30:216-23.